Light and shadows in the iron chelation treatment of haematological diseases.

@article{Maggio2007LightAS,
  title={Light and shadows in the iron chelation treatment of haematological diseases.},
  author={Aurelio Maggio},
  journal={British journal of haematology},
  year={2007},
  volume={138 4},
  pages={407-21}
}
This review outlines the main chelator groups studied to date, and the evidence for their clinical effectiveness. For each treatment, the strength of evidence was documented according to the guidelines from the American College of Cardiology and the American Heart Association. Three main haematological diseases were considered as models: thalassaemia major, sickle-cell disorders and myelodysplasia. Although the data in the literature do not allow firmly evidence-based conclusions, the findings… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Sickle Cell Disease: A Brief Update.

The Medical clinics of North America • 2017

Oral deferiprone for iron chelation in people with thalassaemia.

The Cochrane database of systematic reviews • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…